Exploring the Therapeutic Potential of Entheogens in Postoperative Cognitive Decline and Psychological Resilience
ACS Medicinal Chemistry Letters August 21, 2024 DOI: 10.1021/acsmedchemlett.4c00412 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Psilocybin |
| Keywords | Surgical-medicine Mental-health Cognitive-function Psychedelics |
| Key findings | Entheogens like psilocybin may offer a novel approach to mitigating cognitive decline and enhancing psychological resilience in patients undergoing anesthesia and sedation. |
Abstract
Recent advancements in medical research have focused on the utilization of entheogens, particularly psilocybin and its related compounds, as therapeutic agents in mitigating cognitive decline and enhancing psychological resilience in patients undergoing anesthesia and sedation. This Patent Highlight integrates findings from three patent applications, each contributing unique insights into the potential applications of these substances in medical settings. The article examines the therapeutic mechanisms, proposed treatment methods, and potential clinical outcomes, offering an overview of this innovative approach to postoperative care.
Citations in the library
Cites 2
- Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants Chemical Reviews November 30, 2023
- Mitochondrial Metabolism in Major Depressive Disorder: From Early Diagnosis to Emerging Treatment Options. Journal of Clinical Medicine March 17, 2024